CTOs on the Move

Oxis International

www.oxis.com

 
Oxis International, Inc. has formed and provided initial financing to support the activities of its wholly owned subsidiary, Oxis Biotech, Inc. The parent company, Oxis International is engaged in the research, development and sale of products to counteract oxidative stress and inflammation. Oxis Biotech is focused on the acquisition of cannabis related intellectual properties and commercialization of therapies developed from the intellectual properties to treat certain diseases.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.oxis.com
  • 468 N Camden Dr
    Beverly Hills, CA USA 90210
  • Phone: 650.212.2568

Executives

Name Title Contact Details

Similar Companies

Mighty Oak Medical

Navigate. Dont complicate.™ Personalized patient-specific spine care starts here. Navigate. Dont complicate.™ Personalized patient-specific spine care starts here. Mighty Oak Medical named Solution Provider

Breckenridge Pharmaceutical

Breckenridge Pharmaceutical Inc. is a Boca Raton, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Diffusion Pharmaceuticals

Neuralink is a team of exceptionally talented people. We are creating the future of brain-machine interfaces: building devices now that will help people with paralysis and inventing new technologies that will expand our abilities, our community, and our world. Our goal is to build a system with at least two orders of magnitude more communication channels (electrodes) than current clinically-approved devices. This system needs to be safe, it must have fully wireless communication through the skin, and it has to be ready for patients to take home and use on their own. Our device, called the Link, will be able to record from 1024 electrodes and is designed to meet these criteria.

Oncternal

Oncternal Therapeutics is a clinical-stage oncology company developing a diverse pipeline of treatments for cancers with critical unmet medical need. Oncternal focuses drug development on promising yet untapped biological pathways implicated in cancer progression. The pipeline includes cirmtuzumab, a monoclonal antibody in Phase 1/2 development that inhibits the ROR1 receptor in various hematologic cancers; TK-216, a small-molecule in Phase 1 development that inhibits ETS-family oncoproteins, as a treatment for Ewing sarcoma, a rare pediatric cancer; and a CAR-T therapy that targets ROR1 currently in preclinical development as a potential treatment for solid tumors and hematologic cancers. Based in San Diego, Oncternal is committed to advancing its pipeline rapidly and efficiently to bring patients a new wave of first-in-class cancer treatments.

Children's Crisis Treatment Center

CCTC passionately serves the emotional needs of children and families at risk beginning in early childhood.